Dr. Graff on the Role of Checkpoint Inhibitors in Prostate Cancer

Julie Graff, MD
Published: Tuesday, Dec 26, 2017



Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

According to Graff, there is potential for CTLA-4, PD-1, and PD-L1 to move into prostate cancer. However, there are 2 negative studies of ipilimumab (Yervoy). Therefore, that may not move forward unless it is combined with another therapy or patients are molecularly tested and it is determined as an appropriate form of therapy. There are multiple studies looking at PD-1 therapies in combination.

Additionally, PARP inhibition for patients with tumors expressing DNA-repair defects is very promising, explains Graff. There is a trial out of the National Cancer Institute looking at the PARP inhibitor olaparib (Lynparza) with the PD-1 inhibitor durvalumab (Imfinzi) that is showing promising results.
 


Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the role of checkpoint inhibitors and PARP inhibitors for patients with prostate cancer.

According to Graff, there is potential for CTLA-4, PD-1, and PD-L1 to move into prostate cancer. However, there are 2 negative studies of ipilimumab (Yervoy). Therefore, that may not move forward unless it is combined with another therapy or patients are molecularly tested and it is determined as an appropriate form of therapy. There are multiple studies looking at PD-1 therapies in combination.

Additionally, PARP inhibition for patients with tumors expressing DNA-repair defects is very promising, explains Graff. There is a trial out of the National Cancer Institute looking at the PARP inhibitor olaparib (Lynparza) with the PD-1 inhibitor durvalumab (Imfinzi) that is showing promising results.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x